An2 Therapeutics Stock Today
| ANTX Stock | USD 2.50 0.24 8.76% |
Performance0 of 100
| Odds Of DistressOver 55
|
AN2 Therapeutics is trading at 2.50 as of the 16th of April 2024; that is -8.76 percent decrease since the beginning of the trading day. The stock's open price was 2.74. AN2 Therapeutics has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for AN2 Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of October 2023 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 2022 | Category Healthcare | Classification Health Care |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. An2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 29.77 M outstanding shares of which 272.51 K shares are presently shorted by private and institutional investors with about 0.63 trading days to cover. More on AN2 Therapeutics
Moving together with AN2 Stock
| 0.66 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against AN2 Stock
| 0.85 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.77 | RZLT | Rezolute Trending | PairCorr |
| 0.75 | CCCC | C4 TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
| 0.74 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
| 0.71 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
| 0.68 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
| 0.62 | HOWL | Werewolf Therapeutics Upward Rally | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 9th of May 2024
AN2 Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AN2 Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AN2 Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Partner, Director | Gail Boudreaux | |||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering AN2 Therapeutics report their recommendations after researching AN2 Therapeutics' financial statements, talking to executives and customers, or listening in on AN2 Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering AN2 Therapeutics. The AN2 consensus assessment is calculated by taking the average forecast from all of the analysts covering AN2 Therapeutics. | ||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to AN2 Therapeutics' liquidity, profitability, solvency, and operating efficiency, AN2 Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of AN2 Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||
AN2 Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to AN2 Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AN2 Therapeutics' financial leverage. It provides some insight into what part of AN2 Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
AN2 Therapeutics (ANTX) is traded on NASDAQ Exchange in USA. It is located in 1800 El Camino Real, Menlo Park, CA, United States, 94027 and employs 41 people. AN2 Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AN2 Therapeutics's market, we take the total number of its shares issued and multiply it by AN2 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AN2 Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.77 M outstanding shares of which 272.51 K shares are presently shorted by private and institutional investors with about 0.63 trading days to cover.
AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check AN2 Therapeutics Probability Of Bankruptcy
Ownership AllocationAN2 Therapeutics secures a total of 29.77 Million outstanding shares. Over half of AN2 Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Hence, these institutions are subject to different rules and regulations than regular investors in AN2 Therapeutics. Please watch out for any change in the institutional holdings of AN2 Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AN2 Ownership Details
AN2 Stock Price Odds Analysis
Based on a normal probability distribution, the odds of AN2 Therapeutics jumping above the current price in 90 days from now is about 78.47%. The AN2 Therapeutics probability density function shows the probability of AN2 Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3377. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, AN2 Therapeutics will likely underperform. Additionally, aN2 Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of AN2 Therapeutics to move above the current price in 90 days from now is about 78.47 (This AN2 Therapeutics probability density function shows the probability of AN2 Stock to fall within a particular range of prices over 90 days) .
AN2 Stock Institutional Holders
Institutional Holdings refers to the ownership stake in AN2 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of AN2 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AN2 Therapeutics' value.| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2023-12-31 | 305.8 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 187.4 K | |
| Geode Capital Management, Llc | 2023-12-31 | 178.6 K | |
| Citigroup Inc | 2023-12-31 | 160.5 K | |
| Amvescap Plc. | 2023-12-31 | 157.9 K | |
| Longwood Capital Partners Llc | 2023-12-31 | 132 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 99.4 K | |
| Qube Research & Technologies | 2023-12-31 | 72.2 K | |
| Jane Street Group, Llc | 2023-12-31 | 59.4 K | |
| Ra Capital Management, Llc | 2023-12-31 | 5.6 M | |
| Tcg Crossover Management, Llc | 2023-12-31 | 2.7 M |
AN2 Therapeutics Historical Income Statement
AN2 Therapeutics Income Statement is one of the three primary financial statements used for reporting AN2's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of AN2 Therapeutics revenue and expense. AN2 Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, AN2 Therapeutics' Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 15.5 M in 2024, despite the fact that Depreciation And Amortization is likely to grow to (1 M). View More FundamentalsAN2 Stock Against Markets
Picking the right benchmark for AN2 Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in AN2 Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for AN2 Therapeutics is critical whether you are bullish or bearish towards AN2 Therapeutics at a given time. Please also check how AN2 Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in AN2 Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
AN2 Therapeutics Corporate Directors
AN2 Therapeutics corporate directors refer to members of an AN2 Therapeutics board of directors. The board of directors generally takes responsibility for the AN2 Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of AN2 Therapeutics' board members must vote for the resolution. The AN2 Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Robert Dixon | Independent Director | Profile | |
| Julie Hill | Independent Director | Profile | |
| John Short | Independent Director | Profile | |
| Will Feest | Senior Director Investor Relations | Profile |
How to buy AN2 Stock?
Before investing in AN2 Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in AN2 Therapeutics. To buy AN2 Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of AN2 Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase AN2 Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located AN2 Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased AN2 Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as AN2 Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.
Already Invested in AN2 Therapeutics?
The danger of trading AN2 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AN2 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AN2 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AN2 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AN2 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AN2 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of An2 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on An2 Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for AN2 Stock analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is AN2 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AN2 Therapeutics. If investors know AN2 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AN2 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.36) | Return On Equity (0.59) |
The market value of AN2 Therapeutics is measured differently than its book value, which is the value of AN2 that is recorded on the company's balance sheet. Investors also form their own opinion of AN2 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is AN2 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AN2 Therapeutics' market value can be influenced by many factors that don't directly affect AN2 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AN2 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AN2 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AN2 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.